Zetia angioedema labeling update
Executive Summary
Schering-Plough/Merck Zetia labeling update includes addition of postmarketing experience section in "Adverse Reactions" section. 1Updated label notes that hypersensitivity reactions, including angioedema and rash, have been reported during ezetimibe's postmarketing experience. Schering submitted a "changes being effected" supplement April 3. The cholesterol agent was approved Oct. 25 (2"The Pink Sheet" Nov. 4, 2002, p. 5)...
You may also be interested in...
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.